Efficacy of Immunotherapy in Shaping the Market
Immunotherapy is increasingly recognized as the only disease-modifying treatment for allergic rhinitis, positioning it as a cornerstone in the Allergic Rhinitis Market analysis. Subcutaneous (SCIT) and sublingual (SLIT) immunotherapy regimens target underlying allergic causes rather than just symptoms.
Advancements in allergen extraction techniques and standardized dosing have improved safety and efficacy. Clinics offering multi-year immunotherapy protocols are seeing patients experience longer remission and reduced reliance on symptomatic medications.
The appeal lies in long-term benefits. As immunotherapy becomes accessible via self-administration and faster formulations, it’s expected to capture increasing market share—from allergists to primary care providers.